Clinical Trials Browser

Neoplasm Metastasis, Sarcoma

Carcinoma, Hepatocellular

Liver Metastasis Colon Cancer

Colorectal Neoplasms

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Colorectal Neoplasms

MSI-H Colorectal Cancer

Colorectal Neoplasms

Colorectal Neoplasms

Carcinoma, Hepatocellular

Neoplasm Metastasis

Osteosarcoma

Chondroma, Chondrosarcoma, Osteosarcoma

Thyroid Neoplasms

Carcinoma, Adenoid Cystic

Gastrointestinal Stromal Tumors

Carcinoma, Hepatocellular

Colorectal Neoplasms

Ovarian Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Glioblastoma

Colonic Neoplasms

Colorectal Neoplasms

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Rectal Neoplasms

Advanced Colorectal Cancer in the Third-line Treatment and Beyond

Colorectal Neoplasms

Carcinoma, Hepatocellular

Stomach Neoplasms

Rectal Neoplasms

Liver Metastases

Colonic Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Neoplasm Metastasis

Colorectal Neoplasms

Microsatellite Stable Metastatic Colorectal Cancer

Colorectal Neoplasms

Hematologic Neoplasms

Fatigue, Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Carcinoma, Hepatocellular

Colorectal Neoplasms

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

Liposarcoma, Rhabdomyosarcoma, Osteosarcoma, Chondrosarcoma, Mesenchymal

Clinical Trials

EREMISS

REGO-SARC

Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

DREAM

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

TAPUR

PARERE

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

MegaMOST

SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

REGOBONE

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

LEAF-02

Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

x-МАР

SED-RO-ICC

Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.

SOREGATT

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

a-MANTRA

MIRAGE

REGINA

Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis

THYMI

CARE

REPROGRAM-01

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

SLOT

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

FINPROVE

Efficacy of Ginseng for Patients on Regorafenib

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes